Insulin analogues in children and teens with type 1 diabetes: advantages and caveats

Marianna Rachmiel; Kusiel Perlman; Denis Daneman

doi:10.1016/j.pcl.2005.07.010

Insulin analogues in children and teens with type 1 diabetes: advantages and caveats

Pediatr Clin North Am. 2005 Dec;52(6):1651-75. doi: 10.1016/j.pcl.2005.07.010.

Authors

Marianna Rachmiel¹, Kusiel Perlman, Denis Daneman

Affiliation

¹ Division of Endocrinology, Department of Pediatrics, The Hospital for Sick Children and University of Toronto, 555 University Avenue, Toronto, Ontario, Canada M5G 1X8.

PMID: 16301087
DOI: 10.1016/j.pcl.2005.07.010

Abstract

This article reviews the advantages to and caveats of the use of newer insulin formulations (insulin analogues) and regimens in children and teens who have type 1 diabetes, their affect on glycemic control, frequency of hypoglycemic events, daily insulin requirements, and adverse affects such as excessive weight gain, which provides a further major challenge in adolescents. We also address briefly the use of adjunctive agents in the treatment of type 1 diabetes in children and teens.

Publication types

Review

MeSH terms

Adolescent
Amyloid / therapeutic use
Child
Diabetes Mellitus, Type 1 / drug therapy*
Glucagon-Like Peptide 1 / therapeutic use
Humans
Hypoglycemic Agents / therapeutic use
Insulin / administration & dosage
Insulin / analogs & derivatives
Insulin / analysis
Insulin / therapeutic use*
Insulin Glargine
Insulin, Long-Acting
Islet Amyloid Polypeptide
Metformin / therapeutic use

Substances

Amyloid
Hypoglycemic Agents
Insulin
Insulin, Long-Acting
Islet Amyloid Polypeptide
Insulin Glargine
Glucagon-Like Peptide 1
Metformin
pramlintide